Newer retinoid drugs are effective for skin conditions but have significant side effects.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
December 2023 in “Journal of Ayub Medical College Abbottabad” Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.
May 2022 in “Reactions Weekly” January 2026 in “Rinsho Shinkeigaku” Finasteride and minoxidil may increase stroke risk by affecting blood clotting and blood pressure.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
August 2025 in “ACS Omega” New compounds show promise as nonsteroidal treatments for hair loss.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
May 2019 in “Gastroenterology” Androgen lowering medications don't significantly change HCV-related liver cancer risk in men.
January 2024 in “Pharmaceutical journal/The pharmaceutical journal” Ritlecitinib can help about 14,000 people with severe hair loss.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
December 2006 in “Cancer Epidemiology and Prevention Biomarkers” Primary care doctors rarely use cancer prevention drugs due to concerns about side effects, costs, and effectiveness.
December 2023 in “Research Square (Research Square)” 12-Methoxy carnosic acid from rosemary might be a good natural treatment for hair loss.
1 citations
,
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib effectively regrows hair in severe alopecia areata, especially in adolescents.
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
Finasteride may increase stroke risk in people with clotting tendencies.
4 citations
,
July 1987 in “Dermatologic Clinics”
28 citations
,
September 2013 in “Expert Opinion on Therapeutic Patents” New resveratrol-related compounds show promise for treating various health issues but need more research for clinical use.
May 2026 in “Mendeley Data” May 2026 in “Mendeley Data” April 2026 in “Mendeley Data”
January 2006 in “Revista Argentina de Urología” Finasteride lowers prostate cancer risk but may increase high-grade tumors and sexual side effects.
November 2025 in “Drug Testing and Analysis” Epristeride's metabolism involves key metabolites and proteins, affecting its use in doping tests.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
January 2023 in “Discovery medicine” Cepharanthine helps reduce cell aging caused by the cancer drug Doxorubicin by boosting cell cleanup processes.
November 2008 in “Journal of Generic Medicines” The document updates on EU legal changes, including pharmaceutical patents, class actions in Italy, and various drug-related rulings.
January 2025 in “International Journal of Drug Delivery Technology” A reliable method was developed to measure Finasteride and Tadalafil together, showing they degrade under certain conditions.